Humanized and chimeric monoclonal antibodies to CD99
US10040862B2 · kind B2 · utility
1Cited by
3References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 17, 2015 |
| Grant date | Aug 7, 2018 |
| Priority date | — |
| Expiry date | Apr 17, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Humanized or chimeric anti-CD99 monoclonal antibodies are provided. The antibodies bind to and neutralize human CD99, and find use in various therapeutic methods. Embodiments of the invention include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the humanized or chimeric anti-CD99 monoclonal antibodies; and cell lines that produce these monoclonal antibodies. Also provided are amino acid sequences of the antibodies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.